News - Defymed

News

Home News

Defymed strengthens its position as a worldwide leader

February 13 2018

Strasbourg, France, February 2018 – French-based Medtech company Defymed confirms its global position. Recognized by its peers for the development of two innovative medical devices – ExOlin®, an insulin delivery device, and MailPan®, a bioartificial pancreas – the company intends to strengthen its position as a worldwide leader in innovative phys...

Defymed at ATTD (Booth #33) in Vienna – Austria

February 05 2018

Vienna, February 14-17th 2018: We are happy to announce that Defymed won the “Startup Grant for the...

Upgrade of Defymed’s certification to meet the ISO13485:2016 requirements

January 10 2018

Strasbourg, January 10th 2018: Defymed is proud to announce that its quality management system was a...

Defymed at BIO-Europe in Berlin – Germany

September 28 2017

Berlin, November 6-8th 2017: Defymed is happy to announce that we will be present at the 23rd annual...

Defymed at the 53rd annual meeting of the EASD in Lisbon – Portugal

July 21 2017

Lisbon, September 11-15th 2017: Defymed will particpate at the 53rd annual meeting of the European A...

ExOlin ®, a new insulin delivery device under development by Defymed

July 10 2017

Strasbourg, 10th July 2017: Targeted at persons suffering from diabetes (Type 1 diabetics and some T...

FP7 European collaborative project BIOSID reaches its end

June 12 2017

Strasbourg, 12th June 2017 : BIOSID is an European project coordinated by the European Diabetes Stud...

Defymed at the JDRF Encapsulation Consortium – New York

May 04 2017

11-12 May 2017: Defymed will be present at the JDRF Encapsulation Consortium that will be held in New York – USA. Defymed will present the latest results on MailPan ®’s Bioartificial Pancreas development. This privileged group gathers worldwide key opinion leaders in the field of Cell therapy and Encapsulation for the treatment of Type1 Diabetes. For more in...

Defymed will be present at IPITA congress – Oxford

May 04 2017

20-23 June 2017: Defymed’s team will be present at the 16th international congress IPITA that will be held in Oxford – UK. Defymed will give a talk on the latest results of the bioartificial pancreas MailPan ® at the “Islet encapsulation & bioengineered scaffolds” session that will take place on June 22, from 11:45 to 12:45. This worldwide leading congr...

Defymed at the 1rst MEDFIT Business Convention – Grenoble

May 04 2017

28-29 June 2017: Defymed will particpate at the 1rst MEDFIT convention that will be held in Grenoble- France. MedFIT is the first European business convention dedicated to innovation partnerships in the field of medical technologies, diagnostics and IVD. The event gathers all the actors in the innovation cycle from research to market in addition to key playe...

Defymed enters partnership with Semma Therapeutics

December 12 2016

Strasbourg, December 12, 2016 – Defymed announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the...

Defymed winner of the Medstartup-Galien Awards 2016

October 28 2016

DEFYMED October 27, 2016 – New York. Defymed is the winner at the Medstartup- Galien Awards 2016 – C...

Defymed and Symbiose biomaterials funded for the CODEPI project

October 27 2016

October 26, 2016. Defymed and Symbiose Biomaterials SA, a Belgian startup company specialised in the development of products based on molecular biomimetics, mounted the CODEPI project. This project, cofunded by the Alsace and Wallonian regions, with the help of the health clusters Alsace Biovalley and BIOWIN, aims to develop a compress impregnated with a for...

Defymed nominated for the Medstartup awards 2016 in New York

September 06 2016

September 6, 2016: Defymed is nominated for the Medstartup awards 2016, an initiative of the Galien Foundation & Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. In the frame of this contest, Defymed collaborates with Semma Therapeutics to obtain a preclinical v...

Defymed Receives Support from JDRF to Fight Type 1 Diabetes

July 12 2016

Strasbourg, July 12, 2016. Defymed today announced a partnership with JDRF, the leading global organization funding type 1 diabetes (T1D) research. This new investment gives Defymed the opportunity to advance its pre-clinical studies in order to demonstrate the MailPan ® immunoprotection properties, safety and function. This is an essential step before begin...

Defymed at BIOPHARM AMERICA– Boston

July 11 2016

13-15 Septembre 2016: Defymed will be present at the BIOPHARM AMERICA exhibition 2016 in Boston- USA. That event will be a great opportunity to discuss our latest news and to Partner together. We are looking forward to meeting you! Contact us For more info on Biopharm

Defymed at RESI conference – Boston

July 11 2016

13 Septembre 2016: Defymed’s CEO, Dr Séverine SIGRIST will be present at the RESI conference 2016 in Boston- USA. It will be a great opportunity to meet you and discuss Defymed’s innovations and business. Contact us For more info on RESI

Defymed rewarded at the 44th International exhibition of Inventions Geneva

April 19 2016

April 15, 2016: Defymed received the “INPI prize” and a “gold medal with congratulations of the jury...

Defymed will be exhibiting at the 44th International Exhibition of Inventions Geneva

January 20 2016

13-17 April 2016: Defymed will be exhibiting at the 44th International Exhibition of Inventions Geneva – Switzerland. With more than 750 participants – from a record of 48 countries – and around 1’000 inventions, the International Exhibition of Inventions of Geneva has confirmed its position as the world’s most important specialized meeting place. Many exhib...